Health Care·Biotechnology·$109.4B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $1.30 | N/A | +17.09% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $1.30 | N/A | +17.09% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management remains positive about the company's growth prospects. However, they refrained from offering specific guidance for the upcoming quarters.
Management highlighted strong performance in their key therapeutic areas.
They expressed confidence in their pipeline but did not provide specific guidance.
Vertex Pharmaceuticals reported a strong EPS that exceeded expectations, which is a positive sign for the company's profitability. However, the stock reacted negatively, declining by 0.51%. This could indicate investor caution, possibly due to the lack of revenue data and forward guidance.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
SEAGATE TECHNOLOGY H
Feb 4, 2019